Which Small Cap Healthcare Stocks Are Potential Takeover Targets?
March 24 2011 - 7:35AM
Marketwired
Merger and Acquisition activity in the healthcare sector has been
on the upswing in recent quarters. Going forward larger healthcare
firms are expected to continue searching for smaller, more
speculative companies which are focusing on specific treatments and
specialties in the medical sector. Recent reports suggest that not
only is Big Pharma active in acquisitions, but also larger biotech
firms are showing willingness to utilize their large resource pools
to acquire smaller firms in a race to diversify and to build their
reach. The Bedford Report examines the outlook for companies in the
Healthcare Sector and provides research reports on Orexigen
Therapeutics, Inc. (NASDAQ: OREX) and AEterna Zentaris, Inc.
(NASDAQ: AEZS). Access to the full company reports can be found at:
www.bedfordreport.com/2011-03-OREX
www.bedfordreport.com/2011-03-AEZS
A recent report from Deal Search Online claims that while the
healthcare sector saw a 40 percent drop in the number of M&A
deals last year, the 115 deals in 2010 amounted to $57.5 billion, a
21 percent increase over 2009. The report suggests that the last
decade saw an increase in the amount of deals, led in part by
pharmaceutical companies seeking new blockbuster drugs and products
to fill the void left by drugs coming off patent.
The Bedford Report releases regular market updates on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
A safe and effective obesity drug could have astronomical
earnings potential in North America. Obesity drugs have, however,
proven to be one of the most difficult to gain approval. The FDA
has proven to be very hesitant to approve prospective obesity drugs
due to both safety and efficiency concerns. Recently the FDA dealt
Orexigen a blow when the FDA declined to approve its obesity drug,
Contrave in the present form and issued a complete response letter
(CRL). The FDA stated that it is concerned about the long-term
cardiovascular safety profile of the obesity candidate and has
asked Orexigen to conduct an additional study.
AEterna Zentaris is a late-stage drug development company
specialized in oncology and endocrinology. The company also markets
Cetrotide, a luteinizing hormone-releasing hormone antagonist
treatment approved for in vitro fertilization.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024